Boehringer Ingelheim GmbH didn’t tell regulators that adjusting the dose of blood thinner Pradaxa could make it safer, according to a BMJ probe into the drug that’s been linked to patient deaths.
The German company’s own analysis indicated that adjustment of the dosage might help reduce the risk of major bleeding, a feared side effect of blood thinners, Deborah Cohen, BMJ’s investigations editor, wrote today. Internal documents from 2011 showed that some Boehringer employees were concerned that if they advised the monitoring of Pradaxa levels it could damage the marketing case for the drug, the BMJ wrote.
Help employers find you! Check out all the jobs and post your resume.
